secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088037
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q2 revenue $1,057M, adj EPS $0.18; raises full-year guidance
-------------------------------------------------------------------

- Revenue $1,057M (-10% YoY); estimated $90-$110M ERP blackout impact shifted Q2 revenue to Q1.
- Reported net loss $(97)M, adjusted net income $90M; adjusted EBITDA $222M (21.0% of revenue).
- Full-year 2023 guidance raised: revenue $4,350-$4,410M, adjusted EPS $0.80-$0.89, adj. EBITDA $950-$1,010M.
- New $300M accounts receivable securitization facility; proceeds to retire August 2023 bonds.
- EPA completed review of Seresto, confirming continued registration; launched Canine Parvovirus Mab in U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923088037/0001104659-23-088037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465923088037/tm2322859d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer